Octapharma initiates Phase III trial of Panzyga in PANS patients
PANS is characterised by cognitive, behavioural or neurological symptoms. Credit: Gerd Altmann from Pixabay.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more